Healthcare / Medical DistributionBSE
$3.21
-0.01 (-0.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-43.6M · quality 27.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$80M
P/E
4.5x
↓EV/EBITDA
N/A
•ROE
0.2%
↓Gross Margin
-11.3%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.2%
FCF CAGR
—
FCF margin
-126.6%
FCF / Net income
-168.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $117.6M · net income $882000.0 · FCF $-148.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $117.6M | $117.6M | $40.5M | $203.9M | $167.8M |
| Net Income | $882000.00 | $882000.00 | $4.5M | $16.2M | $10.9M |
| EBITDA | $-21.8M | $-21.8M | $-15.8M | $-37.3M | $14.6M |
| EPS | — | — | 0.33 | 1.19 | 0.70 |
| Gross Margin | -11.3% | -11.3% | 61.6% | 5.2% | 17.9% |
| Operating Margin | -19.0% | -19.0% | -39.2% | -18.3% | 8.7% |
| Net Margin | 0.8% | 0.8% | 11.2% | 7.9% | 6.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.17 | 0.39 | 0.35 |
| Current Ratio | 6.82 | 6.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-148.8M | $-148.8M | $53.1M | $-43.6M | $-264.3M |
| Returns | |||||
| ROE | 0.2% | 0.2% | 1.8% | 6.5% | 4.7% |
| Valuation | |||||
| P/E | 4.52 | 4.52 | 34.70 | 11.33 | 23.93 |
| EV/EBITDA | — | — | — | — | 21.38 |
| P/B | 0.18 | 0.18 | 0.62 | 0.74 | 1.13 |
| Growth & Yield | |||||
| Revenue Growth | 190.1% | 190.1% | -80.1% | 21.5% | — |
| EPS Growth | — | — | -72.3% | 70.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.33 → n/d
Residual
-17.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.